Elizabeth A. Wellberg

This study shows tamoxifen reduces subcutaneous adipocyte progenitor self-renewal and adipogenesis by suppressing Wisp2, linking endocrine therapy to metabolic risks like T2D.

This study shows FGFR1 amplification drives ER+ breast cancer brain metastasis in young and aged mice via FGF2 and NCAM1 interactions, with FGFR inhibitors effective in early stages.

This study identifies ETV4 as a mediator of FGF1-driven proliferation and glycolysis in ER-positive breast cancer, linking obesity-related FGF1 production to tumor progression.